Sandoz', Momenta's generic Lovenox challenged by Aventis

By Angela McDaniels

Seattle, Aug. 8 - Aventis Pharmaceuticals Inc. and Aventis Pharma SA began patent-infringement litigation against Sandoz Inc. on Tuesday, according to an 8-K report filed with the Securities and Exchange Commission by Momenta Pharmaceuticals Inc.

Momenta formed a collaboration with Sandoz in 2003 to jointly develop, manufacture and commercialize M-Enoxaparin, a generic version of Aventis' low-molecular weight herapine Lovenox for the treatment of deep vein thrombosis and cardiovascular conditions.

Sandox filed an Abbreviated New Drug Application for M-Enoxaparin with the Food and Drug Administration in August 2005.

Since its inception, all of Momenta's revenues have been derived from the collaboration with Sandoz and consist primarily of reimbursement from Sandoz for research and development services related to M-Enoxaparin, according to the filing.

Under the collaboration agreement, however, Sandoz agreed to indemnify Momenta for any losses resulting from any patent-infringement litigation related to Lovenox.

Momenta is a Cambridge, Mass.-based biotechnology company specializing in the characterization and engineering of complex drugs.

Sandoz is an affiliate of Novartis AG that develops generic drugs.

Aventis Pharmaceuticals is a subsidiary of sanofi-aventis SA, a Paris-based pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.